Limbos Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.40 M
as on 19-06-2024
- Paid Up Capital ₹ 0.40 M
as on 19-06-2024
- Company Age 21 Year, 26 Days
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 1.80 M
as on 19-06-2024
- Revenue 20.52%
(FY 2022)
- Profit 69.06%
(FY 2022)
- Ebitda -65.91%
(FY 2022)
- Net Worth -11.40%
(FY 2022)
- Total Assets -14.13%
(FY 2022)
About Limbos Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.40 M and a paid-up capital of Rs 0.40 M.
The company has closed loans amounting to ₹1.80 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Gagandeep Kataria, Kulwinder Kataria, and Surinder Kataria serve as directors at the Company.
- CIN/LLPIN
U24232PB2003PTC026568
- Company No.
026568
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Nov 2003
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- LocationPunjab, Punjab
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Limbos Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gagandeep Kataria  | Director | 28-Nov-2003 | Current |
| Kulwinder Kataria | Director | 28-Nov-2003 | Current |
| Surinder Kataria | Director | 28-Nov-2003 | Current |
Financial Performance of Limbos Pharmaceuticals.
Limbos Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 20.52% increase. The company also saw a substantial improvement in profitability, with a 69.06% increase in profit. The company's net worth observed a substantial decline by a decrease of 11.4%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Limbos Pharmaceuticals?
In 2019, Limbos Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Yes Bank Limited Creation Date: 21 Mar 2018 | ₹0.60 M | Satisfied |
State Bank Of India Creation Date: 23 Feb 2012 | ₹0.80 M | Satisfied |
Punjab National Bank Creation Date: 11 Dec 2008 | ₹0.40 M | Satisfied |
How Many Employees Work at Limbos Pharmaceuticals?
Unlock and access historical data on people associated with Limbos Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Limbos Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Limbos Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
